** charts after earnings **
Strong
Beat, Guidance: This provider of exome and genome tests is a play on
the shift toward personalized medicine and earlier intervention.
During
the fourth quarter, GeneDx earned an adjusted 77 cents per share,
obliterating forecasts for 16 cents, according to FactSet. Earnings
flipped from a year-earlier loss of 49 cents. Sales grew almost 65% to
$95.6 million, well ahead of calls for $82.2 million.
GeneDx
also guided to $350 million to $360 million in full-year sales. The low
end of the outlook easily beat analysts' forecast for $340.4 million.
GeneDx uses AI to provide genomics-related diagnostic testing.
GeneDx
provides whole genome and exome sequencing to help identify rare
diseases, primarily in children. The genome includes all the DNA in the
body, while reading the exome involves looking at only the
protein-coding genes.
When performed early,
genetic testing can lead to answers that help avoid what Chief Executive
Katherine Stueland calls a "diagnostic odyssey." The company only tests
for diseases where there is a solution — a clinical study, a dietary
change or a treatment.
No comments:
Post a Comment